A1JUE

Lurbinectedin

Created:2025-11-12
Last modified:  2026-07-29
Find related ligands:
Help
Chemical Details
Formal Charge0
Atom Count100
Chiral Atom Count7
Bond Count109
Aromatic Bond Count22
2D diagram of A1JUE
Toggle HydrogenToggle Labels
Chemical Component Summary
NameLurbinectedin
FormulaC41 H44 N4 O10 S
Molecular Weight784.874
TypeNON-POLYMER
Chemical Descriptors
TypeProgramVersionDescriptor
SMILESCACTVS3.385COc1ccc2[nH]c3c(CCN[C]34CS[CH]5[CH]6[CH]7N(C)[CH](Cc8cc(C)c(OC)c(O)c78)[CH](O)N6[CH](COC4=O)c9c%10OCOc%10c(C)c(OC(C)=O)c59)c2c1
SMILESOpenEye OEToolkits2.0.7Cc1cc2c(c(c1OC)O)C3C4C5c6c(c7c(c(c6OC(=O)C)C)OCO7)C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)c9c(c1cc(ccc1[nH]9)OC)CCN8
Canonical SMILESCACTVS3.385 COc1ccc2[nH]c3c(CCN[C@]34CS[C@H]5[C@H]6[C@@H]7N(C)[C@@H](Cc8cc(C)c(OC)c(O)c78)[C@H](O)N6[C@@H](COC4=O)c9c%10OCOc%10c(C)c(OC(C)=O)c59)c2c1
Canonical SMILESOpenEye OEToolkits2.0.7 Cc1cc2c(c(c1OC)O)[C@@H]3[C@@H]4[C@H]5c6c(c7c(c(c6OC(=O)C)C)OCO7)[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)c9c(c1cc(ccc1[nH]9)OC)CCN8
InChIInChI1.06 InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
InChIKeyInChI1.06 YDDMIZRDDREKEP-HWTBNCOESA-N
Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank IDDB12674 
NameLurbinectedin
Groups
  • investigational
  • approved
DescriptionLurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and small-cell lung cancer (SCLC).[A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor.[A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents.[L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
SynonymsLurbinectedin
Brand NamesZepzelca
IndicationLurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[L14327] It is also indicated in combination with [atezolizumab] (or atezolizumab/hyaluronidase) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab (or atezolizumab/hyaluronidase), [carboplatin], and [etoposide].[L14327]
Categories
  • Alkylating Drugs
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
ATC-CodeL01XX69
CAS number497871-47-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
DNA-unknownadduct
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
AlbuminMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...unknownbinder
Alpha-1-acid glycoprotein 1MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDRITGKWFYIASAF...unknownbinder
ATP-dependent translocase ABCB1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate,inhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682